PeerView Press Home Page
Before beginning, scroll to review all program information. To proceed, you must click the "Start This Activity" button.

CME credit expired on June 7, 2013 and is no longer available.

Activity Description & Educational Objectives

In this activity, experts in rheumatology discuss practical strategies to overcome challenges associated with management of the patient with early RA, including appropriate assessment of disease activity and the subsequent effect on treatment decisions.

Upon completion of this activity, participants should be better able to:

  • Differentiate among currently available and validated tools for assessing rheumatoid arthritis (RA) disease activity, focusing on relative advantages, disadvantages, and ease of use in daily practice
  • Recognize the impact of early treatment and tight control on long-term patient outcomes in RA
  • Discuss the value of individualizing therapy based on patient factors and treat-to-target goals
  • Implement evidence-based data regarding the use of disease-modifying agents in the treatment of patients with RA to achieve tight disease control
  • Describe the impact of adequate treatment on the comorbidities associated with RA
  • Apply a multidisciplinary approach to achieve optimal outcomes in patients with RA

Target Audience

This activity has been designed to meet the educational needs of rheumatologists, rheumatology nurses, and other clinicians involved in the management of patients with RA.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Internet
Release and Expiration Dates: June 08, 2012 - June 07, 2013
Time to Complete: 45 minutes

Faculty & Disclosure / Conflict of Interest Policy

In accordance with ACCME requirements, Penn State College of Medicine has a conflict of interest policy that requires faculty to disclose relevant financial relationships related to the content of their presentations/materials. Any potential conflicts are resolved so that presentations are evidence-based and scientifically balanced.

Course Director and Moderator

Joseph A. Markenson, MD, FACP
Professor of Clinical Medicine
Joan and Sanford Weill Medical College of Cornell University
Hospital for Special Surgery
Internal Medicine & Rheumatology
New York, New York

Joseph A. Markenson, MD, FACP, has a financial interest/relationship or affiliation in the form of:

Speakers Bureau participant with Abbott Laboratories; Amgen Inc.; AstraZeneca; Bristol-Myers Squibb; Covidien; Eli Lilly and Company; Pfizer Inc.; and UCB, Inc.;

Advisory Board for Abbott Laboratories; Amgen Inc.; Pfizer Inc.; and UCB, Inc.

Interviewees

Allan Gibofsky, MD, JD, FACP, FCLM
Professor of Medicine and Public Health
Weill Medical College of Cornell University
Hospital for Special Surgery
Fordham University School of Law
New York, New York

Allan Gibofsky, MD, JD, FACP, FCLM, has a financial interest/relationship or affiliation in the form of:

Consultant for Abbott Laboratories; Amgen Inc.; Hoffmann-La Roche Inc./Genentech, Inc.; Pfizer Inc.; and UCB, Inc.

Speakers Bureau participant with Abbott Laboratories, Amgen Inc.; Pfizer Inc.; and UCB, Inc.

Shareholder in Abbott Laboratories; Amgen Inc.; Bristol-Myers Squibb; GlaxoSmithKline; and Johnson & Johnson Services, Inc.

Advisory Board for Eli Lilly and Company; Horizon Pharma; Iroko Pharmaceuticals, LLC; and Takeda Pharmaceutical Company.

Yusuf Yazici, MD
Assistant Professor
New York University School of Medicine
NYU Hospital for Joint Diseases
New York, New York

Yusuf Yazici, MD, has a financial interest/relationship or affiliation in the form of:

Consultant for Abbott Laboratories; Bristol-Myers Squibb Company; Celgene Corporation; Centocor Ortho Biotech Inc.; Genentech, Inc.; Takeda Pharmaceutical Company; and UCB Pharma, Inc.;

Grant/Research Support from Bristol-Myers Squibb Company; Centocor Ortho Biotech Inc.; and Genentech, Inc.

Medical Director

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, currently has no financial interests/relationships or affiliations in relation to this activity.

Other PVI staff who may potentially review content for this activity have disclosed no relevant financial relationships.

Penn State College of Medicine staff and faculty involved in the development and review of this activity have disclosed no relevant financial relationships.

Sponsorship, Credit & Support

CME credit expired on June 7, 2013 and is no longer available.

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of Penn State College of Medicine and PVI, PeerView Institute for Medical Education. Penn State College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

The Penn State College of Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Information about CME credit for this activity is available by contacting Penn State at 717-531-6483 or ContinuingEd@hmc.psu.edu. Reference course # G5075-12-T.

This CME activity is jointly sponsored by Penn State College of Medicine and PVI, PeerView Institute for Medical Education.

This activity is supported by an educational grant from UCB, Inc.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports.

Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings.

 

We do not recognize you as a registered member.
Please log in by selecting your specialty below:

I have read the required activity information
Start This Activity